Capricor Therapeutics Faces Securities Class Action Lawsuit; Investor Deadline Approaching
Investors with losses exceeding $100,000 have a September 28, 2026 deadline to file lead plaintiff applications in a securities class action lawsuit against Capricor Therapeutics.
Investors who incurred losses of more than $100,000 in Capricor Therapeutics, Inc. securities are reminded that the deadline to seek lead plaintiff status in a class action lawsuit against the company is September 28, 2026.
The lawsuit alleges that Capricor Therapeutics and its executives made materially false or misleading statements regarding the company's business, products, and future prospects. Specifically, the complaint suggests that the company failed to adequately disclose information about the clinical results of its treatment, CAP-1002, or its marketing efforts.
According to the lawsuit, investors purchased Capricor Therapeutics stock at inflated prices based on the company's public statements. When the alleged true nature of the company's situation was revealed, the stock price reportedly declined significantly, causing financial harm to investors.
Shareholders who wish to be appointed lead plaintiff must file their applications with the court by the September 28 deadline. The lawsuit seeks to recover damages on behalf of the class. Those who lost money are encouraged to consult with legal counsel to understand their rights and the litigation process.